Literature DB >> 60920

Changes in thoracic and right duct lymph flow and enzyme content during skeletal muscle stimulation.

C P Bolter, J B Critz.   

Abstract

In the pentobarbital-anaesthetized dog the effect of electrical stimulation of hindlimb skeletal muscles on thoracic and right duct lymph flow and enzyme content was examined. Increase in plasma creatine kinase (CK), L-aspartate-aminotransferase (AST) and lactic dehydrogenase (LDH) during 30-min muscle stimulation were not significantly altered by draining lymph. Both right duct and thoracic duct lymph flow trebled during stimulation. At the same time, the activity of the three enzymes examined decreased in right duct lymph and increased in thoracic duct lymph. Of the latter, only the increase in lymph CK was of a sufficient magnitude to have resulted in a detectable increase in plasma CK. CK was the smallest of the three enzymes studied and apparently preferentially entered the lymph, suggesting that the larger AST and LDH molecules were not likely to have entered the blood plasma directly from skeletal muscle. Rather their entry from some other tissue, possibly the formed elements of the blood, is indicated.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 60920     DOI: 10.3109/13813457609072353

Source DB:  PubMed          Journal:  Arch Int Physiol Biochim        ISSN: 0003-9799


  3 in total

Review 1.  Neuromuscular electrical stimulation. An overview and its application in the treatment of sports injuries.

Authors:  D A Lake
Journal:  Sports Med       Date:  1992-05       Impact factor: 11.136

Review 2.  Creatine kinase in the dog: a review.

Authors:  M Aktas; D Auguste; H P Lefebvre; P L Toutain; J P Braun
Journal:  Vet Res Commun       Date:  1993       Impact factor: 2.459

3.  The effect of an 8-week treatment program using a novel foot neuromuscular electrical stimulator on physical function, leg pain, leg symptoms, and leg blood flow in community-dwelling older adults: a randomized sham-controlled trial.

Authors:  Binoy Kumaran; Darren Targett; Tim Watson
Journal:  Trials       Date:  2022-10-14       Impact factor: 2.728

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.